Orthopedics
Trauma & Reconstruction
Osteoconductive scaffold support for high-energy trauma, revision surgery, tumor resection, and critical long-bone defects.
Next-GenerationSynthetic Bone Graftfor Critical-Size Defects
GraftID combines calcium phosphate and magnesium phosphate biomaterials expertise with controlled resorption and regenerative microenvironment design. The goal: a better-balanced process between new bone formation and material resorption.
100% Synthetic
TÜBİTAK 1812 BiGG
Patent Application Filed
Technological Approach
GraftID designs a platform that supports the pace of new bone formation while preserving the material's functional presence. Controlled resorption, osteoconduction, and a regenerative microenvironment come together in a single product.
Controlled Resorption
Built on beta-tricalcium phosphate and K-struvite, the material is designed to maintain its functional presence at the defect site for a clinically meaningful period.
Osteoconductive Architecture
A porous scaffold that supports natural bone architecture, providing space for cell attachment and tissue integration during new bone formation.
Fully Synthetic Composition
Contains no animal- or human-derived material. The 100% synthetic composition offers supply and standardization advantages as an alternative to biologically sourced grafts.
Clinical Applications
The initial target market is orthopedic and dental applications in Türkiye. The product platform is designed to be adaptable to additional surgical disciplines over time.
Dentistry
Implantology & Augmentation
Graft forms suitable for surgical use in implantology, periodontal, and maxillofacial bone augmentation.
Neurosurgery
Cranial & Spinal Surgery
An adaptable product platform open to development for suitable indications in cranial and spinal surgery.
Future potential:
Veterinary Orthopedics
Research Market
Why GraftID?
Balanced Timing
A design focused on balancing the timing between resorption and new bone formation, so the graft maintains its function long enough in critical defects.
Positioned for Critical-Size Defects
The product is specifically positioned for critical-size bone defects, where fast-resorbing synthetic grafts fall short.
Adaptable Product Platform
An injectable structure plus granule, paste, and other formats adaptable to different surgical indications — a multi-form product platform.
Microstructure visualization
The porous osteoconductive scaffold provides space for tissue integration and vascularization.
R&D and Validation Status
Lab-scale formulation and in vitro validation studies have been carried out under the TÜBİTAK 1812 project, with positive findings on the targeted biological activity.
Work AreaCurrent StatusStage
Formulation development
Completed / optimization ongoing
Completed
Physicochemical characterization
XRD, FTIR, morphology, particle size, swelling and degradation tests
Completed
In vitro biocompatibility
Cytotoxicity and cellular response studies
Completed
Osteogenic validation
Pre-osteoblast models and mineralization-focused analyses
Completed
Osteoclast response
RAW264.7 and RANKL-based resorption mechanism studies
Completed
Animal study
Small-animal bone defect model; studies at an advanced stage
In progress
Sterilization and shelf life
Gamma sterilization and packaging validation plan
Planned
Production scale-up
Pilot production and process standardization being planned
Planned
Note: GraftID is at the pre-seed / product validation and regulatory preparation stage.
Strategic partnerships
Let's develop together
Get in touch with our team for distribution, clinical collaboration, co-development, and investment discussions. We are building a medical technology platform extending from Türkiye to Europe.
- Orthopedic and dental product distributors
- Hospitals, clinics, and early-adopter centers
- Medical device manufacturers and pilot production partners
- Universities and research laboratories
GRAFTID Teknoloji ve Sanayi A.Ş.
Headquarters
Teknopark Istanbul — Cube Incubation
Founder
Asst. Prof. İlayda Duru Türkmen
Field of Activity
Medical technologies, biomaterials, and regenerative medicine